AI Article Synopsis
- Twenty long-term benzodiazepine users, who had been off the medication for an average of 42 months, were tested against two matched controls (one with anxiety, one without).
- Results showed that long-term use is linked to reduced verbal memory, motor skills, and nonverbal memory, with these issues lasting beyond 6 months after stopping the drug.
- Nonverbal memory issues may not be entirely due to benzodiazepine use, as anxiety levels in participants could also be a contributing factor.
Article Abstract
Twenty participants with self-reported long-term benzodiazepine use (mean 108 months) who had previously withdrawn from medication (mean 42 months) were administered a battery of neuropsychological tests. Each long-term user was case matched for age, sex, and education to two control participants who reported never taking benzodiazepines (those with and those without anxiety). The results indicated that long-term benzodiazepine use may lead to impairments in the areas of verbal memory, motor control/performance, and nonverbal memory but not visuospatial skills and attention/concentration. The length of abstinence (> 6 months) indicates that these impairments persist well beyond cessation of benzodiazepine use. However, observed impairments in the area of nonverbal memory were not solely attributable to benzodiazepine use and may be influenced by the elevated anxiety levels present in both the case and the anxious control group.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1017/S1355617705050332 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Improving the physical health of overweight/obese people suffering from severe mental disorders: What is the role of antipsychotic drugs and of lifestyle psychosocial interventions?
J Psychiatr Res
November 2024
Department of Psychiatry, University of Campania "Vanvitelli", Italy.
People with severe mental disorders experience premature mortality compared with the general population. Several factors contribute to the mortality gap, including the adoption of unhealthy lifestyle behaviours, poor screening for physical illnesses, difficulties in accessing healthcare facilities, specific clinical features of mental disorders and some pharmacological treatment such as antipsychotic medications with serious metabolic side effects. In the present study, carried out in the framework of the LIFESTYLE trial, a funded nationwide multicentric study, we aimed to assess the impact of different antipsychotics in mediating the effectiveness of psychosocial intervention on healthy lifestyle behaviours.
View Article and Find Full Text PDFPatient characteristics in relation to opioid exposure in a chronic non-cancer pain population.
Scand J Pain
January 2024
Department of Clinical Sciences Malmö, Center for Primary Health Care Research, Lund University, Jan Waldenströms Gata 35, 202 13 Malmö, Sweden.
Objectives: The efficacy of long-term opioid therapy (LTOT) in treating patients with chronic non-cancer pain (CnCP) is questionable, and the potential risks of adverse effects are well established. The aims were as follows: (1) compare characteristics in patients exposed to LTOT vs non-exposed. (2) Regarding opioid-exposed patients, describe characteristics of patients with risk factors for opioid use disorder or overdose in relation to opioid dosage.
View Article and Find Full Text PDFA prospective cohort of treatment-seeking patients with problematic use of prescription narcotic drugs: study protocol and baseline characteristics.
BMC Psychiatry
December 2024
The Stockholm Centre for Dependency Disorders, Stockholm Health Care Services, Region Stockholm, Friskvårdsvägen 4, Stockholm, 112 81, Sweden.
Background: There is limited knowledge on long-term outcomes of tapering treatment for individuals with problematic use of prescription narcotics, including opioids and benzodiazepines. The overall aim of the study is to investigate clinical trajectories and treatment outcomes of patients seeking treatment in addiction care.
Methods: This paper presents the study protocol and baseline characteristics of a cohort of patients seeking treatment for problematic use of prescription narcotic drugs at specialized outpatient addiction services.
Association of remimazolam with delirium and cognitive function: A systematic review and meta-analysis of randomised controlled trials.
Eur J Anaesthesiol
December 2024
From the Universidade Federal da Bahia, Hospital Ana Nery, Salvador, Brazil (JAA), Universidade Federal da Fronteira Sul, Passo Fundo (GRMW), Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil (BFMW), Escola Bahiana de Medicina e Saúde Pública, Salvador, Brazil (LSS), São Paulo (FJLB) and Universidade de São Paulo, São Paulo, Brazil (RGMF).
Background And Study Objective: Delirium is an organic mental syndrome significantly associated with long-term cognitive decline, increased hospital stays and higher mortality. This systematic review of randomised controlled trials (RCTs) with meta-analysis assesses the association of remimazolam with postoperative cognitive function and delirium compared with non-benzodiazepine hypnotics.
Design: Systematic review of RCTs with meta-analysis.
[Not Available].
Recenti Prog Med
December 2024
Sezione Assistenza farmaceutica, integrativa e protesica, Regione Umbria, Perugia.
Aim of the study was to assess the use of pharmacological therapies provided in Nursing Homes and Protected Residences of the Umbria Region, with reference to central nervous system medications. In 2022, 200 ddd (defined daily doses) per 100 bed-days were administered in Umbria's long term care facilities, representing a 6.2% decrease compared to the previous year.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!